A recent study highlights microneedling with tranexamic acid as a promising treatment for melasma. Researchers report strong clinical improvement and high patient satisfaction rates.
Melasma is a common skin disorder that causes brown facial pigmentation. It often relapses and resists long-term treatment. Dermatologists continue searching for more effective and safe therapies.
Study evaluates microneedling with tranexamic acid
The new study evaluates microneedling combined with tranexamic acid, also known as TXA. Microneedling creates tiny skin channels to enhance drug delivery. TXA helps reduce melanin production and pigmentation.
Researchers compare three treatment approaches
Researchers conducted a randomised controlled study involving female patients with facial melasma. They divided participants into three treatment groups for comparison. One group received microneedling with TXA. Another group received microneedling with metformin. The third group used a modified topical formula.
TXA group shows the strongest improvement
All groups showed improvement in pigmentation levels after treatment. However, the TXA microneedling group achieved the strongest results. This group recorded the highest reduction in melasma severity scores.
The TXA group showed about 45 per cent improvement in pigmentation severity. The metformin group showed lower improvement levels. The control group also improved but at a slower rate.
Patient satisfaction remains highest with TXA
Researchers measured outcomes using the modified Melasma Area and Severity Index. They also assessed patient satisfaction and side effects. The TXA group reported the highest satisfaction scores among all participants.
More patients in the TXA group described marked cosmetic improvement. Participants tolerated the procedure well across all groups. Researchers reported minimal side effects during the study period.
Safety profile supports the procedure
Pain levels remained similar between microneedling groups. No serious adverse events occurred during the trial. This finding supports the safety of the procedure.
Combination therapy enhances drug delivery
Researchers explain that microneedling enhances drug penetration into the skin. TXA then acts directly on pigment pathways. This combination improves treatment efficiency compared to topical therapy alone.
Experts suggest that melasma treatment requires multiple therapeutic approaches. Sun protection, topical agents, and procedural treatments often work together. This study supports combining procedural and pharmacological methods.
Evidence builds for tranexamic acid use
Previous studies also support the use of TXA in pigmentation disorders. Research shows that TXA reduces melanin activity and inflammation. Microneedling further boosts its effectiveness by improving absorption.
Systematic reviews also confirm that microneedling with TXA improves clinical outcomes. However, experts note that more large-scale trials remain necessary. They recommend further research to confirm long-term safety and durability.
Dermatologists call for long-term strategies
Dermatologists view melasma as a chronic and recurring condition. Many patients experience relapse after initial improvement. Therefore, long-term management strategies remain essential.
Study concludes strong clinical potential
The new findings provide additional evidence for combination therapies. They suggest that targeted delivery methods can improve treatment response. This approach may reshape future dermatology practices.
Researchers conclude that microneedling with TXA offers a promising treatment option. They highlight its effectiveness, safety, and patient satisfaction. However, they emphasise the need for further clinical validation.
The study strengthens growing evidence for advanced melasma therapies. It also supports innovation in drug delivery techniques for skin disorders. Dermatologists may adopt this approach in future treatment protocols.
Overall, the study shows clear improvement in melasma outcomes. It positions microneedling with TXA as a leading emerging therapy. Further research may confirm its role in standard dermatological care.